App-Quantinova.ai

Overcoming EGFR-induced resistance to enzalutamide in castration-resistant prostate cancer

Thomas M. Steele - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Oseltamivir phosphate completely ablates tumor refractoriness to conventional chemotherapeutics abraxane and gemcitabine in xenografts of tumors in mouse model of human pancreatic cancer

Myron R. Szewczuk - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Oseltamivir

Reversal of cisplatin resistance in human ovarian cancer through autophagy inhibition and caspase 1- activation: Role of tumor associated Vacuolar-ATPase

Arpita Kulshrestha - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Verapamil and tamoxifen modulate ABCB1 expression in multidrug-resistant cells and resensitize them to conventional chemotherapy

Georgia Limniatis - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Calan

Modulating the function of multidrug resistance ABCG2 transporter by tyrosine kinases receptor inhibitor cabozantinib

Guannan Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

Successfully targeting triple negative breast cancer using combination therapy of Didox and Doxorubicin with reduced cardiotoxicity

Elizabeth A. Wilson - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Targeting the BET bromodomain proteins and anti-apoptotic protein BCL2 in small cell lung cancer

Lloyd T. Lam - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Navitoclax

Mechanism-based combination strategies for BET inhibitors in NUT midline carcinoma

Anastasia Wyce - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

I-BET151

ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

Emily J. Faivre - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Functional group elaboration of a low molecular weight fragment to yield the novel BET family bromodomain inhibitor ABBV-075

Keith McDaniel - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

abbv-075

BET protein inhibitors prevent TKI-induced drug resistance in solid tumors

Yuan Zhao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vemurafenib

The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models

Bernard Haendler - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers

Huawei (Ray) Chen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

AZD5153

Investigating the role of EZH2 as a therapeutic target in clear cell renal cell carcinoma (ccRCC)

Darmood Wei - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tazemetostat

BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer

Kanak Raina - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Broad anti-tumor activity of a novel BET bromodomain inhibitor

Yan Ma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Molibresib

In vivo efficacy of BET inhibitor BAY 1238097 in preclinical models of melanoma and lung cancer

Olaf Klingbeil - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications

Aparna Sarthy - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

abbv-075

Innovative cancer treatment of human lung cancer cells PC-9 with a synthetic retinoid Am80 and EGCG via inhibition of HDAC4 and HDAC5

Masami Suganuma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tretinoin

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell-mediated lysis of prostate and breast carcinoma cells

Sofia R. Gameiro - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Entinostat

Filters

41730 Abstracts